Mar 31, 2026 04:07PM
Mar 31, 2026 04:06PM
Mar 31, 2026 04:05PM
Mar 2, 2026 07:30AM
Mar 2, 2026 07:30AM
Dec 31, 2025 07:00AM
Dec 31, 2025 07:00AM BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma
Nov 21, 2025 03:56AM
Nov 21, 2025 12:25AM
Nov 13, 2025 04:05PM
Oct 23, 2025 08:02AM
Oct 23, 2025 08:00AM
Sep 9, 2025 04:02AM
Sep 8, 2025 08:00AM BioAtla gets FDA alignment on phase 3 trial design for cancer drug
Sep 8, 2025 08:00AM
Aug 7, 2025 04:05PM
Jun 2, 2025 08:07AM
Jun 2, 2025 08:00AM
May 6, 2025 04:05PM
Mar 27, 2025 04:05PM
Dec 16, 2024 08:00AM BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in
Nov 13, 2024 06:51AM
Nov 7, 2024 04:01PM
Sep 23, 2024 07:31AM
Sep 23, 2024 07:30AM
Sep 16, 2024 08:01AM
Sep 16, 2024 08:00AM
Sep 9, 2024 08:00AM BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
Aug 28, 2024 08:00AM
Aug 8, 2024 04:05PM
Aug 1, 2024 08:00AM
Jul 25, 2024 05:39PM
Jul 23, 2024 08:00AM
May 23, 2024 05:05PM
May 14, 2024 04:05PM BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
May 8, 2024 08:00AM
May 7, 2024 08:00AM
May 6, 2024 08:02AM
May 6, 2024 08:00AM
Mar 26, 2024 04:01PM
Dec 5, 2023 08:00AM
Nov 28, 2023 08:00AM BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
Nov 7, 2023 04:01PM
Aug 1, 2023 04:01PM
Aug 1, 2023 04:01PM
May 11, 2023 04:01PM
Mar 23, 2023 04:05PM
Mar 23, 2023 04:05PM
Feb 23, 2023 08:00AM BioAtla (BCAB) Announces FDA Clearance of Investigational New Drug Application for BA3182
Feb 23, 2023 08:00AM

322,963 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All